Valneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate

An announcement from Valneva ( (VALN) ) is now available.

On March 23, 2026, Valneva and Pfizer reported topline Phase 3 results from the VALOR trial of their jointly developed 6‑valent OspA-based Lyme disease vaccine candidate PF‑07307405 (LB6V), showing more than 70% efficacy in preventing Lyme disease in people aged five and older and a favorable safety profile. Although fewer-than-expected Lyme cases meant the primary statistical criterion was not met in the first pre‑specified analysis, a second analysis delivered a confidence interval above the key threshold, bolstering Pfizer’s confidence and positioning Valneva more firmly in the high‑value Lyme vaccine space as the partners move toward regulatory submissions in a market with no approved human Lyme vaccines and rising medical need.

These data underscore Valneva’s strategy of building a differentiated, late‑stage vaccine portfolio alongside its commercial travel franchise, potentially unlocking a significant new revenue stream if approval is granted and shifting competitive dynamics in vector‑borne disease prevention. For stakeholders, the progress in the Lyme program highlights both the opportunity in addressing a growing Northern Hemisphere health burden and the usual development and regulatory risks that can affect timelines, labeling and eventual commercial uptake.

The most recent analyst rating on (VALN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

The score is primarily held down by weak financial performance—large losses, ongoing cash burn, and elevated leverage—despite improving gross margin. Technicals are mixed with a longer-term uptrend but muted momentum. The earnings call adds some support via maintained guidance and pipeline progress, but near-term product and profitability headwinds remain, and valuation is constrained by negative earnings.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The group applies a targeted, multi-modality approach to deliver first-, best- or only-in-class vaccines and currently generates revenue from three proprietary travel vaccines, which supports the advancement of its broader vaccine pipeline.

Average Trading Volume: 17,740

Technical Sentiment Signal: Buy

Current Market Cap: $906.4M

Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.